EF
PTGX icon

Empowered Funds’s Protagonist Therapeutics PTGX Stock Holding History

Empowered Funds’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Sell
2,264
-57
-2% -$5.95K ﹤0.01% 1886
2026
Q1 		$245K Buy
+2,321
New +$206K ﹤0.01% 1926
2025
Q2 		– Sell
-102,532
Closed -$4.96M – 1828
2025
Q1 		$4.96M Buy
+102,532
New +$4.3M 0.07% 391

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Empowered Funds's PTGX Position: Q2 2026 in Review

Empowered Funds reduced its Protagonist Therapeutics (PTGX) stake by 2.5% in Q2 2026, selling an estimated $5.95K and leaving 2,264 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #1886.

Empowered Funds first reported a position in PTGX in Q1 2025 and has held it in 3 quarters since. The position peaked at $4.96M in Q1 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Empowered Funds held 2,264 shares of Protagonist Therapeutics worth $278K as of Q2 2026.
  • Empowered Funds sold 57 Protagonist Therapeutics shares in Q2 2026, an estimated $5.95K.
  • Protagonist Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #1886 holding.
  • Empowered Funds first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Empowered Funds's Protagonist Therapeutics position peaked at $4.96M in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.